XML 88 R77.htm IDEA: XBRL DOCUMENT
v3.19.1

Segment Reporting - Sales of Company's Products (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2019 | Mar. 31, 2018
Segment Reporting Information [Line Items] |  |
Sales | $ 10,816 | $ 10,037
Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 10,727 | 10,068
Other |  |
Segment Reporting Information [Line Items] |  |
Sales | 89 | (31)
United States |  |
Segment Reporting Information [Line Items] |  |
Sales | 4,515 | 4,133
United States | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 4,508 | 4,107
United States | Other |  |
Segment Reporting Information [Line Items] |  |
Sales | 7 | 26
International |  |
Segment Reporting Information [Line Items] |  |
Sales | 6,301 | 5,904
International | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 6,219 | 5,960
International | Other |  |
Segment Reporting Information [Line Items] |  |
Sales | 82 | (56)
Total Pharmaceutical segment sales | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 9,663 | 8,919
Total Pharmaceutical segment sales | Operating Segments | Keytruda |  |
Segment Reporting Information [Line Items] |  |
Sales | 2,269 | 1,464
Total Pharmaceutical segment sales | Operating Segments | Emend |  |
Segment Reporting Information [Line Items] |  |
Sales | 117 | 125
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lynparza |  |
Segment Reporting Information [Line Items] |  |
Sales | 79 | 33
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lenvima |  |
Segment Reporting Information [Line Items] |  |
Sales | 74 | 0
Total Pharmaceutical segment sales | Operating Segments | Gardasil/Gardasil 9 |  |
Segment Reporting Information [Line Items] |  |
Sales | 838 | 660
Total Pharmaceutical segment sales | Operating Segments | ProQuad/M-M-R II/Varivax |  |
Segment Reporting Information [Line Items] |  |
Sales | 496 | 392
Total Pharmaceutical segment sales | Operating Segments | RotaTeq |  |
Segment Reporting Information [Line Items] |  |
Sales | 211 | 193
Total Pharmaceutical segment sales | Operating Segments | Pneumovax 23 |  |
Segment Reporting Information [Line Items] |  |
Sales | 185 | 179
Total Pharmaceutical segment sales | Operating Segments | Vaqta |  |
Segment Reporting Information [Line Items] |  |
Sales | 47 | 37
Total Pharmaceutical segment sales | Operating Segments | Bridion |  |
Segment Reporting Information [Line Items] |  |
Sales | 255 | 204
Total Pharmaceutical segment sales | Operating Segments | Noxafil |  |
Segment Reporting Information [Line Items] |  |
Sales | 190 | 176
Total Pharmaceutical segment sales | Operating Segments | Cubicin |  |
Segment Reporting Information [Line Items] |  |
Sales | 88 | 98
Total Pharmaceutical segment sales | Operating Segments | Invanz |  |
Segment Reporting Information [Line Items] |  |
Sales | 72 | 151
Total Pharmaceutical segment sales | Operating Segments | Cancidas |  |
Segment Reporting Information [Line Items] |  |
Sales | 61 | 91
Total Pharmaceutical segment sales | Operating Segments | Primaxin |  |
Segment Reporting Information [Line Items] |  |
Sales | 59 | 72
Total Pharmaceutical segment sales | Operating Segments | Simponi |  |
Segment Reporting Information [Line Items] |  |
Sales | 208 | 231
Total Pharmaceutical segment sales | Operating Segments | Remicade |  |
Segment Reporting Information [Line Items] |  |
Sales | 123 | 167
Total Pharmaceutical segment sales | Operating Segments | Belsomra |  |
Segment Reporting Information [Line Items] |  |
Sales | 67 | 54
Total Pharmaceutical segment sales | Operating Segments | Isentress/Isentress HD |  |
Segment Reporting Information [Line Items] |  |
Sales | 255 | 281
Total Pharmaceutical segment sales | Operating Segments | Zepatier |  |
Segment Reporting Information [Line Items] |  |
Sales | 114 | 131
Total Pharmaceutical segment sales | Operating Segments | Zetia |  |
Segment Reporting Information [Line Items] |  |
Sales | 140 | 305
Total Pharmaceutical segment sales | Operating Segments | Vytorin |  |
Segment Reporting Information [Line Items] |  |
Sales | 97 | 167
Total Pharmaceutical segment sales | Operating Segments | Atozet |  |
Segment Reporting Information [Line Items] |  |
Sales | 94 | 73
Total Pharmaceutical segment sales | Operating Segments | Adempas |  |
Segment Reporting Information [Line Items] |  |
Sales | 90 | 68
Total Pharmaceutical segment sales | Operating Segments | Januvia |  |
Segment Reporting Information [Line Items] |  |
Sales | 824 | 880
Total Pharmaceutical segment sales | Operating Segments | Janumet |  |
Segment Reporting Information [Line Items] |  |
Sales | 530 | 544
Total Pharmaceutical segment sales | Operating Segments | NuvaRing |  |
Segment Reporting Information [Line Items] |  |
Sales | 219 | 216
Total Pharmaceutical segment sales | Operating Segments | Implanon/Nexplanon |  |
Segment Reporting Information [Line Items] |  |
Sales | 199 | 174
Total Pharmaceutical segment sales | Operating Segments | Singulair |  |
Segment Reporting Information [Line Items] |  |
Sales | 191 | 175
Total Pharmaceutical segment sales | Operating Segments | Cozaar/Hyzaar |  |
Segment Reporting Information [Line Items] |  |
Sales | 103 | 120
Total Pharmaceutical segment sales | Operating Segments | Nasonex |  |
Segment Reporting Information [Line Items] |  |
Sales | 96 | 122
Total Pharmaceutical segment sales | Operating Segments | Arcoxia |  |
Segment Reporting Information [Line Items] |  |
Sales | 75 | 83
Total Pharmaceutical segment sales | Operating Segments | Follistim AQ |  |
Segment Reporting Information [Line Items] |  |
Sales | 57 | 67
Total Pharmaceutical segment sales | Operating Segments | Other Pharmaceutical |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,140 | 1,186
Total Pharmaceutical segment sales | United States | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 4,175 | 3,716
Total Pharmaceutical segment sales | United States | Operating Segments | Keytruda |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,284 | 838
Total Pharmaceutical segment sales | United States | Operating Segments | Emend |  |
Segment Reporting Information [Line Items] |  |
Sales | 63 | 79
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lynparza |  |
Segment Reporting Information [Line Items] |  |
Sales | 50 | 24
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lenvima |  |
Segment Reporting Information [Line Items] |  |
Sales | 50 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Gardasil/Gardasil 9 |  |
Segment Reporting Information [Line Items] |  |
Sales | 362 | 380
Total Pharmaceutical segment sales | United States | Operating Segments | ProQuad/M-M-R II/Varivax |  |
Segment Reporting Information [Line Items] |  |
Sales | 343 | 312
Total Pharmaceutical segment sales | United States | Operating Segments | RotaTeq |  |
Segment Reporting Information [Line Items] |  |
Sales | 154 | 151
Total Pharmaceutical segment sales | United States | Operating Segments | Pneumovax 23 |  |
Segment Reporting Information [Line Items] |  |
Sales | 125 | 112
Total Pharmaceutical segment sales | United States | Operating Segments | Vaqta |  |
Segment Reporting Information [Line Items] |  |
Sales | 29 | 18
Total Pharmaceutical segment sales | United States | Operating Segments | Bridion |  |
Segment Reporting Information [Line Items] |  |
Sales | 119 | 80
Total Pharmaceutical segment sales | United States | Operating Segments | Noxafil |  |
Segment Reporting Information [Line Items] |  |
Sales | 91 | 81
Total Pharmaceutical segment sales | United States | Operating Segments | Cubicin |  |
Segment Reporting Information [Line Items] |  |
Sales | 42 | 47
Total Pharmaceutical segment sales | United States | Operating Segments | Invanz |  |
Segment Reporting Information [Line Items] |  |
Sales | 14 | 91
Total Pharmaceutical segment sales | United States | Operating Segments | Cancidas |  |
Segment Reporting Information [Line Items] |  |
Sales | 1 | 3
Total Pharmaceutical segment sales | United States | Operating Segments | Primaxin |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 5
Total Pharmaceutical segment sales | United States | Operating Segments | Simponi |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Remicade |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Belsomra |  |
Segment Reporting Information [Line Items] |  |
Sales | 24 | 23
Total Pharmaceutical segment sales | United States | Operating Segments | Isentress/Isentress HD |  |
Segment Reporting Information [Line Items] |  |
Sales | 108 | 128
Total Pharmaceutical segment sales | United States | Operating Segments | Zepatier |  |
Segment Reporting Information [Line Items] |  |
Sales | 33 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Zetia |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 17
Total Pharmaceutical segment sales | United States | Operating Segments | Vytorin |  |
Segment Reporting Information [Line Items] |  |
Sales | 3 | 8
Total Pharmaceutical segment sales | United States | Operating Segments | Atozet |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Adempas |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Januvia |  |
Segment Reporting Information [Line Items] |  |
Sales | 384 | 465
Total Pharmaceutical segment sales | United States | Operating Segments | Janumet |  |
Segment Reporting Information [Line Items] |  |
Sales | 167 | 192
Total Pharmaceutical segment sales | United States | Operating Segments | NuvaRing |  |
Segment Reporting Information [Line Items] |  |
Sales | 185 | 171
Total Pharmaceutical segment sales | United States | Operating Segments | Implanon/Nexplanon |  |
Segment Reporting Information [Line Items] |  |
Sales | 149 | 128
Total Pharmaceutical segment sales | United States | Operating Segments | Singulair |  |
Segment Reporting Information [Line Items] |  |
Sales | 5 | 6
Total Pharmaceutical segment sales | United States | Operating Segments | Cozaar/Hyzaar |  |
Segment Reporting Information [Line Items] |  |
Sales | 4 | 7
Total Pharmaceutical segment sales | United States | Operating Segments | Nasonex |  |
Segment Reporting Information [Line Items] |  |
Sales | (1) | 1
Total Pharmaceutical segment sales | United States | Operating Segments | Arcoxia |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Follistim AQ |  |
Segment Reporting Information [Line Items] |  |
Sales | 29 | 29
Total Pharmaceutical segment sales | United States | Operating Segments | Other Pharmaceutical |  |
Segment Reporting Information [Line Items] |  |
Sales | 358 | 320
Total Pharmaceutical segment sales | International | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 5,488 | 5,202
Total Pharmaceutical segment sales | International | Operating Segments | Keytruda |  |
Segment Reporting Information [Line Items] |  |
Sales | 985 | 626
Total Pharmaceutical segment sales | International | Operating Segments | Emend |  |
Segment Reporting Information [Line Items] |  |
Sales | 53 | 46
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lynparza |  |
Segment Reporting Information [Line Items] |  |
Sales | 29 | 9
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lenvima |  |
Segment Reporting Information [Line Items] |  |
Sales | 24 | 0
Total Pharmaceutical segment sales | International | Operating Segments | Gardasil/Gardasil 9 |  |
Segment Reporting Information [Line Items] |  |
Sales | 476 | 280
Total Pharmaceutical segment sales | International | Operating Segments | ProQuad/M-M-R II/Varivax |  |
Segment Reporting Information [Line Items] |  |
Sales | 153 | 80
Total Pharmaceutical segment sales | International | Operating Segments | RotaTeq |  |
Segment Reporting Information [Line Items] |  |
Sales | 57 | 42
Total Pharmaceutical segment sales | International | Operating Segments | Pneumovax 23 |  |
Segment Reporting Information [Line Items] |  |
Sales | 59 | 66
Total Pharmaceutical segment sales | International | Operating Segments | Vaqta |  |
Segment Reporting Information [Line Items] |  |
Sales | 18 | 18
Total Pharmaceutical segment sales | International | Operating Segments | Bridion |  |
Segment Reporting Information [Line Items] |  |
Sales | 136 | 124
Total Pharmaceutical segment sales | International | Operating Segments | Noxafil |  |
Segment Reporting Information [Line Items] |  |
Sales | 99 | 94
Total Pharmaceutical segment sales | International | Operating Segments | Cubicin |  |
Segment Reporting Information [Line Items] |  |
Sales | 46 | 51
Total Pharmaceutical segment sales | International | Operating Segments | Invanz |  |
Segment Reporting Information [Line Items] |  |
Sales | 58 | 60
Total Pharmaceutical segment sales | International | Operating Segments | Cancidas |  |
Segment Reporting Information [Line Items] |  |
Sales | 60 | 88
Total Pharmaceutical segment sales | International | Operating Segments | Primaxin |  |
Segment Reporting Information [Line Items] |  |
Sales | 59 | 67
Total Pharmaceutical segment sales | International | Operating Segments | Simponi |  |
Segment Reporting Information [Line Items] |  |
Sales | 208 | 231
Total Pharmaceutical segment sales | International | Operating Segments | Remicade |  |
Segment Reporting Information [Line Items] |  |
Sales | 123 | 167
Total Pharmaceutical segment sales | International | Operating Segments | Belsomra |  |
Segment Reporting Information [Line Items] |  |
Sales | 44 | 31
Total Pharmaceutical segment sales | International | Operating Segments | Isentress/Isentress HD |  |
Segment Reporting Information [Line Items] |  |
Sales | 147 | 152
Total Pharmaceutical segment sales | International | Operating Segments | Zepatier |  |
Segment Reporting Information [Line Items] |  |
Sales | 81 | 131
Total Pharmaceutical segment sales | International | Operating Segments | Zetia |  |
Segment Reporting Information [Line Items] |  |
Sales | 140 | 287
Total Pharmaceutical segment sales | International | Operating Segments | Vytorin |  |
Segment Reporting Information [Line Items] |  |
Sales | 94 | 158
Total Pharmaceutical segment sales | International | Operating Segments | Atozet |  |
Segment Reporting Information [Line Items] |  |
Sales | 94 | 73
Total Pharmaceutical segment sales | International | Operating Segments | Adempas |  |
Segment Reporting Information [Line Items] |  |
Sales | 90 | 68
Total Pharmaceutical segment sales | International | Operating Segments | Januvia |  |
Segment Reporting Information [Line Items] |  |
Sales | 440 | 416
Total Pharmaceutical segment sales | International | Operating Segments | Janumet |  |
Segment Reporting Information [Line Items] |  |
Sales | 364 | 352
Total Pharmaceutical segment sales | International | Operating Segments | NuvaRing |  |
Segment Reporting Information [Line Items] |  |
Sales | 34 | 46
Total Pharmaceutical segment sales | International | Operating Segments | Implanon/Nexplanon |  |
Segment Reporting Information [Line Items] |  |
Sales | 50 | 46
Total Pharmaceutical segment sales | International | Operating Segments | Singulair |  |
Segment Reporting Information [Line Items] |  |
Sales | 186 | 170
Total Pharmaceutical segment sales | International | Operating Segments | Cozaar/Hyzaar |  |
Segment Reporting Information [Line Items] |  |
Sales | 99 | 113
Total Pharmaceutical segment sales | International | Operating Segments | Nasonex |  |
Segment Reporting Information [Line Items] |  |
Sales | 97 | 121
Total Pharmaceutical segment sales | International | Operating Segments | Arcoxia |  |
Segment Reporting Information [Line Items] |  |
Sales | 75 | 83
Total Pharmaceutical segment sales | International | Operating Segments | Follistim AQ |  |
Segment Reporting Information [Line Items] |  |
Sales | 28 | 39
Total Pharmaceutical segment sales | International | Operating Segments | Other Pharmaceutical |  |
Segment Reporting Information [Line Items] |  |
Sales | 782 | 867
Total Animal Health segment sales | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,025 | 1,065
Total Animal Health segment sales | Operating Segments | Livestock |  |
Segment Reporting Information [Line Items] |  |
Sales | 611 | 652
Total Animal Health segment sales | Operating Segments | Companion Animals |  |
Segment Reporting Information [Line Items] |  |
Sales | 414 | 413
Total Animal Health segment sales | United States | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 294 | 307
Total Animal Health segment sales | United States | Operating Segments | Livestock |  |
Segment Reporting Information [Line Items] |  |
Sales | 117 | 124
Total Animal Health segment sales | United States | Operating Segments | Companion Animals |  |
Segment Reporting Information [Line Items] |  |
Sales | 177 | 183
Total Animal Health segment sales | International | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 731 | 758
Total Animal Health segment sales | International | Operating Segments | Livestock |  |
Segment Reporting Information [Line Items] |  |
Sales | 494 | 529
Total Animal Health segment sales | International | Operating Segments | Companion Animals |  |
Segment Reporting Information [Line Items] |  |
Sales | 237 | 229
Other segment sales | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 39 | 84
Other segment sales | United States | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 39 | 84
Other segment sales | International | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | $ 0 | $ 0

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_EmendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaqtaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CubicinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZepatierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZetiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VytorinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AtozetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NuvaringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ImplanonNexplanonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SingulairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NasonexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CozaarHyzaarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ArcoxiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_FollistimAqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |